Op-ed: Beyond Clinical Trials - Psychedelic Assisted Therapy in Europe's Real World

Psychedelic-assisted therapy in Europe needs to move beyond clinical trial settings and address real-world delivery. The piece focuses on what changes when treatment moves into everyday healthcare and community contexts, including how regulated access should work, what practical support clinicians and providers need, and how outcomes should be evaluated outside tightly controlled studies. It frames the key challenge as bridging evidence from trials to scalable care while maintaining safety, ethics, and patient-centered standards, not just proving efficacy in controlled research environments.